<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02429583</url>
  </required_header>
  <id_info>
    <org_study_id>CRI-0844</org_study_id>
    <secondary_id>U19AI111825</secondary_id>
    <nct_id>NCT02429583</nct_id>
  </id_info>
  <brief_title>Effects of Persistent Innate Immune Activation on Vaccine Efficacy</brief_title>
  <official_title>Effects of Persistent Innate Immune Activation on Vaccine Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Rockefeller University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the effects of chronic HCV infection and corresponding innate&#xD;
      immune activation on the immune response to HBV vaccination. We will recruit chronic HCV&#xD;
      patients and healthy control patients for HBV vaccination. We will use RNA Sequencing&#xD;
      (RNA-Seq), a relatively new technology for simultaneously measuring the expression of all&#xD;
      genes, to determine patients' innate immune status, and learn how this innate immune&#xD;
      signature is related to HBV vaccine response. We will then explore the mechanisms by which&#xD;
      chronic HCV infection affects different immune cells and functions that are known to be&#xD;
      important for an effective HBV vaccine response. These studies will enhance our understanding&#xD;
      of the immune effects of chronic viral infection, establish factors that determine effective&#xD;
      vaccine responses, and help guide vaccination strategies for HCV patients and other&#xD;
      individuals with chronic inflammatory disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vaccines have been responsible for preventing millions of deaths and extending the average&#xD;
      human lifespan. Effective vaccines stimulate the cells of the immune system to activate genes&#xD;
      and associated functions that bring about protective immunity. If we can better understand&#xD;
      the factors that influence vaccine success versus failure, we may be able to improve current&#xD;
      vaccines and/or develop new vaccines against prevalent infectious diseases.&#xD;
&#xD;
      Certain groups of people do not respond well to particular vaccines. For example, vaccines&#xD;
      can be less effective in immunocompromised patients, elderly individuals, and people with&#xD;
      chronic inflammatory diseases. Often it is these groups of people that have the greatest need&#xD;
      for protection against infectious disease.&#xD;
&#xD;
      People chronically infected with hepatitis C virus (HCV) are at increased risk of serious&#xD;
      liver disease. As a result, they should receive the hepatitis B virus (HBV) vaccine, which&#xD;
      can protect them from infection by HBV, another virus that targets the liver. However, people&#xD;
      chronically infected with HCV do not respond to the HBV vaccine as effectively as healthy&#xD;
      people without HCV. Chronic HCV infection is not thought to cause general problems with the&#xD;
      immune system, and the reasons for this poor vaccine response are poorly understood. Previous&#xD;
      work has shown that chronic HCV infection leads to production of chemical (&quot;innate immune&quot;)&#xD;
      signals that can affect function of the immune system, but it is currently unknown how this&#xD;
      might impact vaccination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to enroll sufficient subjects&#xD;
  </why_stopped>
  <start_date type="Actual">May 8, 2015</start_date>
  <completion_date type="Actual">November 2018</completion_date>
  <primary_completion_date type="Actual">November 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBV Vaccine Response Versus Non-response Status</measure>
    <time_frame>8 months</time_frame>
    <description>Titers of anti-hepatitis B surface antigen antibody measured at 8 months&#xD;
Luminex assay for multiplex cytokine/chemokine panel measured at 8 months RNA-Seq with analysis focus on curated ISG list measured at 8 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and Functional Status of Anti-HBsAg Antibody-producing B Cells Post-vaccination Doses Over Time</measure>
    <time_frame>8 months</time_frame>
    <description>ELISPOT assays will measured at 8 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Functional Status of HBsAg-specific CD4+ &quot;Helper&quot; T Cells</measure>
    <time_frame>8 months</time_frame>
    <description>Flow cytometry assays measured at 8 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Response of Monocytes Stimulated ex Vivo With Vaccine Antigen and/or Adjuvant</measure>
    <time_frame>8 months</time_frame>
    <description>Isolated from patient PBMCs measured at 8 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene Expression Profile of Conventional Dendritic Cells Measured by RNA-Seq</measure>
    <time_frame>8 months</time_frame>
    <description>Isolated from patient PBMCs measured at 8 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>Recombivax in HCV infected individuals</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recombivax vaccine administered IM to HCV-infected individuals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recombivax in healthy volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recombivax vaccine administered IM to healthy individuals</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombivax</intervention_name>
    <description>Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
    <arm_group_label>Recombivax in HCV infected individuals</arm_group_label>
    <arm_group_label>Recombivax in healthy volunteers</arm_group_label>
    <other_name>Hepatitis B vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing to receive three doses of an FDA-approved Hepatitis B vaccine&#xD;
&#xD;
          -  Volunteer chronically infected with HCV (as demonstrated by serology and/or viral load&#xD;
             laboratory studies)&#xD;
&#xD;
          -  Healthy volunteer without significant medical problems&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received any vaccine within a month prior to study vaccine&#xD;
&#xD;
          -  Positive serum antibody against Hep B surface antigen and/or core Hep B core antigen&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  For HCV-negative, healthy volunteers: History of HCV infection or positive HCV&#xD;
             antibody test&#xD;
&#xD;
          -  Participation in another clinical study of an investigational product currently or&#xD;
             within the past 90 days, or expected participation during this study&#xD;
&#xD;
          -  In the opinion of the investigator, the volunteer is unlikely to comply with the study&#xD;
             protocol&#xD;
&#xD;
          -  Any clinically significant abnormality or medical history or physical examination&#xD;
             including history of immunodeficiency or autoimmune disease (in addition to HCV&#xD;
             infection, for HCV group)&#xD;
&#xD;
          -  Currently taking systemic steroids or other immunomodulatory medications including&#xD;
             anticancer medications and antiviral medications&#xD;
&#xD;
          -  Any clinically significant acute or chronic medical condition requiring care by a&#xD;
             primary care provider (e.g., diabetes, coronary artery disease, rheumatologic illness,&#xD;
             malignancy, substance abuse) that, in the opinion of the investigator, would preclude&#xD;
             participation&#xD;
&#xD;
          -  Unable to continue participation for 156 weeks&#xD;
&#xD;
          -  History of previous Hepatitis B vaccination(s)&#xD;
&#xD;
          -  Male or female &lt; 18 and &gt; 62 years of age&#xD;
&#xD;
          -  Is pregnant or lactating&#xD;
&#xD;
          -  History of Hepatitis B infection&#xD;
&#xD;
          -  Clinical, laboratory, or biopsy evidence of cirrhosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>62 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Rice, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Rockefeller University Center for Clinical and Translational</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rockefeller University Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 24, 2015</study_first_submitted>
  <study_first_submitted_qc>April 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2015</study_first_posted>
  <results_first_submitted>February 3, 2020</results_first_submitted>
  <results_first_submitted_qc>February 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 4, 2020</results_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rockefeller University</investigator_affiliation>
    <investigator_full_name>Charles Rice</investigator_full_name>
    <investigator_title>Head of Laboratory of Virology and Infectious Disease</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT02429583/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Recombivax in HCV Infected Individuals</title>
          <description>Recombivax vaccine administered IM to HCV-infected individuals&#xD;
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
        </group>
        <group group_id="P2">
          <title>Recombivax in Healthy Volunteers</title>
          <description>Recombivax vaccine administered IM to healthy individuals&#xD;
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Only 4 participants completed the study. One HCV infected individual enrolled in the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Recombivax in HCV Infected Individuals</title>
          <description>Recombivax vaccine administered IM to HCV-infected individuals&#xD;
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
        </group>
        <group group_id="B2">
          <title>Recombivax in Healthy Volunteers</title>
          <description>Recombivax vaccine administered IM to healthy individuals&#xD;
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="60" upper_limit="60"/>
                    <measurement group_id="B2" value="44" lower_limit="42" upper_limit="49"/>
                    <measurement group_id="B3" value="48" lower_limit="42" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HBV Vaccine Response Versus Non-response Status</title>
        <description>Titers of anti-hepatitis B surface antigen antibody measured at 8 months&#xD;
Luminex assay for multiplex cytokine/chemokine panel measured at 8 months RNA-Seq with analysis focus on curated ISG list measured at 8 months</description>
        <time_frame>8 months</time_frame>
        <population>The data was not collected and the analysis was not completed for this study due to insufficient enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Recombivax in HCV Infected Individuals</title>
            <description>Recombivax vaccine administered IM to HCV-infected individuals&#xD;
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
          </group>
          <group group_id="O2">
            <title>Recombivax in Healthy Volunteers</title>
            <description>Recombivax vaccine administered IM to healthy individuals&#xD;
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>HBV Vaccine Response Versus Non-response Status</title>
          <description>Titers of anti-hepatitis B surface antigen antibody measured at 8 months&#xD;
Luminex assay for multiplex cytokine/chemokine panel measured at 8 months RNA-Seq with analysis focus on curated ISG list measured at 8 months</description>
          <population>The data was not collected and the analysis was not completed for this study due to insufficient enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Functional Status of Anti-HBsAg Antibody-producing B Cells Post-vaccination Doses Over Time</title>
        <description>ELISPOT assays will measured at 8 months</description>
        <time_frame>8 months</time_frame>
        <population>The data was not collected and the analysis was not completed for this study due to insufficient enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Recombivax in HCV Infected Individuals</title>
            <description>Recombivax vaccine administered IM to HCV-infected individuals&#xD;
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
          </group>
          <group group_id="O2">
            <title>Recombivax in Healthy Volunteers</title>
            <description>Recombivax vaccine administered IM to healthy individuals&#xD;
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Functional Status of Anti-HBsAg Antibody-producing B Cells Post-vaccination Doses Over Time</title>
          <description>ELISPOT assays will measured at 8 months</description>
          <population>The data was not collected and the analysis was not completed for this study due to insufficient enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Functional Status of HBsAg-specific CD4+ &quot;Helper&quot; T Cells</title>
        <description>Flow cytometry assays measured at 8 months</description>
        <time_frame>8 months</time_frame>
        <population>The data was not collected and the analysis was not completed for this study due to insufficient enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Recombivax in HCV Infected Individuals</title>
            <description>Recombivax vaccine administered IM to HCV-infected individuals&#xD;
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
          </group>
          <group group_id="O2">
            <title>Recombivax in Healthy Volunteers</title>
            <description>Recombivax vaccine administered IM to healthy individuals&#xD;
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Functional Status of HBsAg-specific CD4+ &quot;Helper&quot; T Cells</title>
          <description>Flow cytometry assays measured at 8 months</description>
          <population>The data was not collected and the analysis was not completed for this study due to insufficient enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Response of Monocytes Stimulated ex Vivo With Vaccine Antigen and/or Adjuvant</title>
        <description>Isolated from patient PBMCs measured at 8 months</description>
        <time_frame>8 months</time_frame>
        <population>The data was not collected and the analysis was not completed for this study due to insufficient enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Recombivax in HCV Infected Individuals</title>
            <description>Recombivax vaccine administered IM to HCV-infected individuals&#xD;
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
          </group>
          <group group_id="O2">
            <title>Recombivax in Healthy Volunteers</title>
            <description>Recombivax vaccine administered IM to healthy individuals&#xD;
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Response of Monocytes Stimulated ex Vivo With Vaccine Antigen and/or Adjuvant</title>
          <description>Isolated from patient PBMCs measured at 8 months</description>
          <population>The data was not collected and the analysis was not completed for this study due to insufficient enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gene Expression Profile of Conventional Dendritic Cells Measured by RNA-Seq</title>
        <description>Isolated from patient PBMCs measured at 8 months</description>
        <time_frame>8 months</time_frame>
        <population>The data was not collected and the analysis was not completed for this study due to insufficient enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Recombivax in HCV Infected Individuals</title>
            <description>Recombivax vaccine administered IM to HCV-infected individuals&#xD;
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
          </group>
          <group group_id="O2">
            <title>Recombivax in Healthy Volunteers</title>
            <description>Recombivax vaccine administered IM to healthy individuals&#xD;
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Gene Expression Profile of Conventional Dendritic Cells Measured by RNA-Seq</title>
          <description>Isolated from patient PBMCs measured at 8 months</description>
          <population>The data was not collected and the analysis was not completed for this study due to insufficient enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 30 weeks</time_frame>
      <desc>Adverse event information was collected from both arms of the study (3 healthy volunteers and 1 HCV infected individual)</desc>
      <group_list>
        <group group_id="E1">
          <title>Recombivax in HCV Infected Individuals</title>
          <description>Recombivax vaccine administered IM to HCV-infected individuals&#xD;
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
        </group>
        <group group_id="E2">
          <title>Recombivax in Healthy Volunteers</title>
          <description>Recombivax vaccine administered IM to healthy individuals&#xD;
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cold Like Symptoms</sub_title>
                <description>Volunteer complained of &quot;cold-like&quot; symptoms (headache, sneezing, scratchy throat) without cough or fever.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Patient Stubbed Toe</sub_title>
                <description>Volunteer reported that he stubbed the great toe of his left foot on 08/19/2015 resulting in moderate pain and discomfort</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Pain at Injection Site</sub_title>
                <description>Volunteer experienced mild tenderness at the right upper arm vaccination site twenty minutes after receiving his first Hepatitis B vaccination which resolved by next day</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Aileen O'Connell, Laboratory Manager</name_or_title>
      <organization>The Rockefeller University</organization>
      <phone>212-327-7047</phone>
      <email>aoconnell@rockefeller.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

